Pangenotypic regimens and the next generation hepatitis C virus therapy.
作者信息
Reau Nancy S
机构信息
Department of Hepatology Rush University Medical Center Chicago IL.
出版信息
Clin Liver Dis (Hoboken). 2017 Jun 29;9(6):131-133. doi: 10.1002/cld.635. eCollection 2017 Jun.
Abstract
摘要
相似文献
1
Pangenotypic regimens and the next generation hepatitis C virus therapy.泛基因型治疗方案与下一代丙型肝炎病毒疗法
Clin Liver Dis (Hoboken). 2017 Jun 29;9(6):131-133. doi: 10.1002/cld.635. eCollection 2017 Jun.
2
Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection.泛基因型直接作用抗病毒药物治疗丙型肝炎病毒感染的真实世界疗效和安全性
Rev Recent Clin Trials. 2019;14(3):173-182. doi: 10.2174/1574887114666190306154650.
3
Evolution of efficacious pangenotypic hepatitis C virus therapies.有效的泛基因型丙型肝炎病毒治疗方法的演变。
Med Res Rev. 2019 May;39(3):1091-1136. doi: 10.1002/med.21554. Epub 2018 Dec 2.
4
Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in "special populations".丙型肝炎的治疗：新型泛基因型直接作用抗病毒药物在“特殊人群”中的应用。
Liver Int. 2018 Feb;38 Suppl 1:28-33. doi: 10.1111/liv.13626.
6
[Treatment of Hepatitis C: State of the Art 2018].[丙型肝炎的治疗：2018年最新进展]
Dtsch Med Wochenschr. 2018 Dec;143(24):1784-1788. doi: 10.1055/a-0591-5916. Epub 2018 Dec 3.
7
Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.直接抗病毒药物治疗丙型肝炎病毒感染的挑战与展望。
J Hepatol. 2018 Nov;69(5):1178-1187. doi: 10.1016/j.jhep.2018.07.002. Epub 2018 Jul 11.
8
On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: A mathematical modelling study.关于短期强化干预对中断男男性行为艾滋病毒感染者丙型肝炎病毒传播的潜力：一项数学建模研究。
J Viral Hepat. 2018 Jan;25(1):10-18. doi: 10.1111/jvh.12752. Epub 2017 Aug 23.
9
Hepatitis C virus resistance to the new direct-acting antivirals.丙型肝炎病毒对新型直接作用抗病毒药物的耐药性。
Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1197-209. doi: 10.1080/17425255.2016.1209484. Epub 2016 Jul 18.
10
High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.缅甸慢性丙型肝炎患者中，使用通用 NS5A 抑制剂和索非布韦方案可实现高持续病毒学应答率。
J Viral Hepat. 2019 Oct;26(10):1186-1199. doi: 10.1111/jvh.13133. Epub 2019 Jun 10.
引用本文的文献
1
Hepatitis C virus screening and treatment in Irish prisons from nurse managers' perspectives - a qualitative exploration.从护士管理者视角看爱尔兰监狱中的丙型肝炎病毒筛查与治疗——一项质性探索
BMC Nurs. 2019 Jun 13;18:23. doi: 10.1186/s12912-019-0347-x. eCollection 2019.
2
Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective.阻碍和促进丙型肝炎（HCV）筛查和治疗的因素——囚犯视角的描述。
Harm Reduct J. 2018 Dec 11;15(1):62. doi: 10.1186/s12954-018-0269-z.
本文引用的文献
1
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.索磷布韦和维帕他韦治疗 2 型和 3 型丙型肝炎病毒感染。
N Engl J Med. 2015 Dec 31;373(27):2608-17. doi: 10.1056/NEJMoa1512612. Epub 2015 Nov 17.
Zotero 插件